Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-06-14
2005-06-14
Raymond, Richard L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S311000, C514S385000, C514S396000, C514S399000, C514S409000, C514S412000, C514S422000, C514S425000, C548S300100, C548S300700, C548S407000, C548S408000, C548S409000, C546S112000, C546S134000, C546S016000
Reexamination Certificate
active
06906053
ABSTRACT:
The present application describes novel hydantoin derivatives of formula (I):or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, B, R1, R2, R3, R4, R5, R6, R7, R11, and n are defined in the present specification, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-α converting enzyme (TACE), aggrecanase, or a combination thereof.
REFERENCES:
patent: 4315031 (1982-02-01), Vincent et al.
patent: 4816454 (1989-03-01), Zoller et al.
patent: 5567725 (1996-10-01), Hemmerle et al.
patent: 5811459 (1998-09-01), Breault et al.
patent: 5821241 (1998-10-01), Claremon et al.
patent: 5861380 (1999-01-01), Gyorkos et al.
patent: 6048877 (2000-04-01), Ahmad et al.
patent: 6268379 (2001-07-01), Xue et al.
patent: 151744 (1973-11-01), None
patent: 5213957 (1993-08-01), None
patent: WO 99/24416 (1999-05-01), None
patent: WO 00/35886 (2000-06-01), None
patent: WO 01/12189 (2001-02-01), None
patent: WO 01/23363 (2001-04-01), None
patent: WO 01/44217 (2001-06-01), None
patent: WO 02/074748 (2002-09-01), None
patent: WO 02/074749 (2002-09-01), None
patent: WO 02/074750 (2002-09-01), None
patent: WO 02/074751 (2002-09-01), None
patent: WO 02/074752 (2002-09-01), None
patent: WO 02/074767 (2002-09-01), None
Chemical Abstract DN 120:271177, also cited as JP 5213957 dated Aug. 1993.
Knabe et al., “Racemates and enantiomers of basic substituted 5-phynylhydantoins. Syntheses and antiarrhythmic activity,” PHARMAZIE, vol. 52 No. 12, 1997, pp. 912-919.
Aharony et al., “Pharmacacological Characterization of a New Class of Non-Peptide Neurokinin A Antagonists that Demonstrate Species Selectivity”,J. Pharmacol. Exp. Ther., 1995, 274(3), pp. 1216-1221.
PubMed Abstract 145790524, also cited asCurr. Opin. Drug Disc., 6/5, 2003, pp. 742-759.
PubMed Abstract 11934805, also cited asBr. J. Pharmacol., 135/7, 2002, pp. 1655-1664.
PubMed Abstract 12082286, also cited asBiorheology, 39/1-2, 2002, pp. 237-246.
PubMed Abstract 14524529, also cited asClin. Exp. Metastasis, 20/5, 2003 pp. 407-412.
Duan Jingwu
Sheppeck James E.
Wasserman Zelda
Xue Chu-Biao
Bristol-Myers Squibb Pharma Company
Patel Sudhaker B.
Raymond Richard L.
Sun Jing G.
LandOfFree
Hydantoins and related heterocycles as inhibitors of matrix... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hydantoins and related heterocycles as inhibitors of matrix..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hydantoins and related heterocycles as inhibitors of matrix... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3500467